Brammer Bio, the best-in-class cell and gene therapy contract development and manufacturing organization, is proud to announce plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The facility will be qualified and operational by Q2 of 2017.Read More
Brammer Bio is a best-in-class cell and gene therapy biologics contract development and manufacturing organization (CDMO).
The merger will combine deep technical expertise with demonstrated capabilities and operating approaches and the quality standards required for commercial manufacturing.
Brammer Bio is focused on providing process development, clinical, and commercial supply of autologous and allogeneic cell therapy, ex vivo gene therapy and viral vector products enabling the delivery of novel medicines and improving patient health.Read More